Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in PAD Patients.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

Also called NCT04229264

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Science Valley Research Institute (from the registry)
Registry
  • NCT NCT04229264
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Brazil (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04229264. Randomized; no masking; primary purpose treatment. Start 2020-01-09 (actual); primary completion 2022-02-02 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in PAD Patients.
Acronym
AGRIPPA
Condition
Critical Limb Ischemia
Intervention (Drug)
Apixaban
Intervention (Drug)
ASA
Intervention (Drug)
Clopidogrel 75mg
Lead sponsor
Science Valley Research Institute (class: other)
Collaborator
Wyeth is now a wholly owned subsidiary of Pfizer (class: industry)

Record details

Record id
cardio:ct-nct04229264
Content hash
61ee3d3a7aa9d2b791ea2db857fdef0a82e8b713664281de016723d68bef8c8e